» Articles » PMID: 39300174

The Role of 2'-5'-oligoadenylate Synthase-like Protein (OASL1) in Biliary and Hepatotoxin-induced Liver Injury in Mice

Overview
Journal Sci Rep
Specialty Science
Date 2024 Sep 19
PMID 39300174
Authors
Affiliations
Soon will be listed here.
Abstract

Following an injury, the liver embarks on a process that drives the accumulation and reformation of the extracellular matrix, leading to hepatic fibrosis. Type I interferons (IFNs), including IFN-α and IFN-β, play a crucial role in averting chronic liver injury through the activation of IFN-stimulated genes (ISGs), which are instrumental in sculpting adaptive immunity. The role of 2'-5'-oligoadenylate synthase-like protein 1 (OASL1), an antiviral ISG, in the context of liver fibrosis remains to be elucidated. To elicit liver fibrosis, a diet containing 0.1% diethoxycarbonyl-1,4-dihydrocollidine (DDC) and carbon tetrachloride (CCl) were employed to induce cholestatic- and hepatotoxin-mediated liver fibrosis, respectively. Histological analyses of both models revealed that OASL1 mice exhibited reduced liver damage and, consequently, expressed lower levels of fibrotic mediators, notably α-smooth muscle actin. OASL1 mice demonstrated significantly elevated IFN-α and IFN-β mRNA levels, regulated by the IFN regulatory factor 7 (IRF7). Additionally, OASL1 ameliorated chronic liver fibrosis through the modulation of nuclear factor-κB (NF-κB) signaling. The effect of OASL1 on type I IFN production in acute liver damage was further explored and OASL1 mice consistently showed lower alanine transaminase levels and pro-inflammatory cytokines, but IFN-α and IFN-β mRNA levels were upregulated, leading to amelioration of acute liver injury. Additionally, the study discovered that F4/80-positive cells were observed more frequently in OASL1 CCl acutely treated mice. This implies that there is a significant synergy in the function of macrophages and OASL1 deficiency. These results demonstrate that in instances of liver injury, OASL1 inhibits the production of type I IFN by modulating the NF-κB signaling pathway, thereby worsening disease.

References
1.
Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y . Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139(2):499-509. DOI: 10.1053/j.gastro.2010.04.049. View

2.
Marcellin P, Kutala B . Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018; 38 Suppl 1:2-6. DOI: 10.1111/liv.13682. View

3.
Friedman S . Liver fibrosis -- from bench to bedside. J Hepatol. 2003; 38 Suppl 1:S38-53. DOI: 10.1016/s0168-8278(02)00429-4. View

4.
Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao G . Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023; 8(1):207. PMC: 10200802. DOI: 10.1038/s41392-023-01452-1. View

5.
Sim C, Lee J, Baek I, Lee S, Lee M . Enhanced Antitumor Immune Response in 2'-5' Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy. J Immunol Res. 2019; 2019:7596786. PMC: 6462330. DOI: 10.1155/2019/7596786. View